Home
SPRC
SPRC News

Latest SciSparc Ltd. (SPRC) News on June 8, 2025

SciSparc Announces Publication of Japanese Patent Application

GlobeNewswire

12 days ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

GlobeNewswire

a month ago

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

GlobeNewswire

a month ago

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

MT Newswires

a month ago

Jeffs' Brands to Sell Smart Repair Pro Unit, SciSparc Nutraceuticals Stake to Plantify Foods; Shares Jump

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

GlobeNewswire

a month ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

GlobeNewswire

3 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

GlobeNewswire

3 months ago

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

GlobeNewswire

3 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

GlobeNewswire

3 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

MT Newswires

3 months ago

N2OFF to Acquire Biotech Firm MitoCareX Bio; Shares Fall

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

GlobeNewswire

3 months ago

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

GlobeNewswire

4 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

GlobeNewswire

4 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

MT Newswires

5 months ago

SciSparc Gets 180-Day Nasdaq Extension to Regain Compliance With Minimum Bid Price Rule

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

GlobeNewswire

5 months ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

GlobeNewswire

5 months ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc says MitoCareX expands research to pancreatic cancer

TipRanks

5 months ago

SciSparc says MitoCareX expands research to pancreatic cancer

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

GlobeNewswire

5 months ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

MT Newswires

5 months ago

Top Midday Gainers

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Benzinga

5 months ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

MT Newswires

5 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT Newswires

5 months ago

SciSparc Says Clearmind Medicine Files European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

GlobeNewswire

5 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

IMCA renews SciSparc’s autism spectrum disorder therapy trial approval

Clinical Trials Arena

5 months ago

IMCA renews SciSparc’s autism spectrum disorder therapy trial approval

MT Newswires

5 months ago

SciSparc Gets Renewal From Israeli Medical Cannabis Agency for Autism Spectrum Disorder Trial

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

GlobeNewswire

5 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

SciSparc: AutoMax announces $13M first delivery of JAC vehicles

TipRanks

5 months ago

SciSparc: AutoMax announces $13M first delivery of JAC vehicles

SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment

Benzinga

5 months ago

SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment

MT Newswires

5 months ago

SciSparc's Merger Target AutoMax Motors Completes $13 Million China Vehicle Import Deal

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

GlobeNewswire

5 months ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

GlobeNewswire

6 months ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Jeffs’ Brands announces trademark registration approval for Wellution

TipRanks

6 months ago

Jeffs’ Brands announces trademark registration approval for Wellution

SciSparc receives FDA approval for trial for Tourette syndrome therapy

Clinical Trials Arena

8 months ago

SciSparc receives FDA approval for trial for Tourette syndrome therapy

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

GlobeNewswire

8 months ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

GlobeNewswire

8 months ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

GlobeNewswire

9 months ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

MT Newswires

9 months ago

Scisparc Submits FDA Investigational New Drug Application for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

GlobeNewswire

9 months ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

MT Newswires

9 months ago

Clearmind Applies for Patent on Anti-Addiction Combination Therapy -- Shares Up After Hours

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

GlobeNewswire

9 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

GlobeNewswire

9 months ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

GlobeNewswire

9 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

GlobeNewswire

9 months ago

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

GlobeNewswire

9 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

GlobeNewswire

9 months ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc secures final approval in Israel to start Tourette’s Syndrome trial

Clinical Trials Arena

9 months ago

SciSparc secures final approval in Israel to start Tourette’s Syndrome trial

SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial

Clinical Trials Arena

9 months ago

SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

GlobeNewswire

9 months ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

GlobeNewswire

10 months ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

GlobeNewswire

10 months ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

SciSparc and Polyrizon sign global agreement for pain therapy

Pharmaceutical Technology

10 months ago

SciSparc and Polyrizon sign global agreement for pain therapy

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

GlobeNewswire

10 months ago

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

SciSparc Updates Regarding the Status of the AutoMax Merger

GlobeNewswire

10 months ago

SciSparc Updates Regarding the Status of the AutoMax Merger

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

GlobeNewswire

10 months ago

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

MT Newswires

a year ago

Scisparc Signs Non-Binding Letter of Intent for Out-Licensing of Potential Pain Treatment

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

GlobeNewswire

a year ago

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

MT Newswires

a year ago

SciSparc Receives Nasdaq Noncompliance Notice

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

GlobeNewswire

a year ago

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

MT Newswires

a year ago

SciSparc Seeks Patent for Obesity Drug Ingredient's Composition

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

GlobeNewswire

a year ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

MT Newswires

a year ago

SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

GlobeNewswire

a year ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

a year ago

Net Asset Value(s)

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

GlobeNewswire

a year ago

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Newsfile

a year ago

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Business Wire

a year ago

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Dstny honored with 'Employee Wellbeing Award'

PR Newswire

a year ago

Dstny honored with 'Employee Wellbeing Award'

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

PR Newswire

a year ago

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

GlobeNewswire

a year ago

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Business Wire

a year ago

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Start Proud Opens the Market

CNW Group

a year ago

Start Proud Opens the Market

Will recreational pot go on sale soon in Ohio? Medical marijuana stores can now apply to sell it

Associated Press Finance

a year ago

Will recreational pot go on sale soon in Ohio? Medical marijuana stores can now apply to sell it

Business Wire

a year ago

Form 8.3 - Darktrace plc

Dow Jones Trims Losses As Yields Spike On Jobs Data; GameStop Dives

Investor's Business Daily

a year ago

Dow Jones Trims Losses As Yields Spike On Jobs Data; GameStop Dives

May jobs reports signals Fed's soft landing: US Labor Secretary

Yahoo Finance Video

a year ago

May jobs reports signals Fed's soft landing: US Labor Secretary

NICE to Webcast Financial Analyst and Investor Day at Interactions 2024

Business Wire

a year ago

NICE to Webcast Financial Analyst and Investor Day at Interactions 2024

Notification of major holding in Kindred Group plc

PR Newswire

a year ago

Notification of major holding in Kindred Group plc

Business Wire

a year ago

Form 8.3 - DS Smith plc

SciSparc Secures Strategic Advantage with Grant of European Patent

GlobeNewswire

a year ago

SciSparc Secures Strategic Advantage with Grant of European Patent

SciSparc to Acquire AutoMax

GlobeNewswire

a year ago

SciSparc to Acquire AutoMax

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

GlobeNewswire

a year ago

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

GlobeNewswire

a year ago

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

GlobeNewswire

a year ago

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

GlobeNewswire

a year ago

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

GlobeNewswire

a year ago

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

GlobeNewswire

a year ago

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

GlobeNewswire

a year ago

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

GlobeNewswire

a year ago

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

GlobeNewswire

a year ago

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds

Benzinga

a year ago

EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

GlobeNewswire

a year ago

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Share on Social Networks: